Investor Relations

Latest Financial Results

FY 2025

Fiscal Year Ended Dec 31, 2025

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2025

Email Alerts

Sign up to stay informed and receive updates directly to your inbox.

Sign Up Today

Company Overview

We are a scientific leader in dermatologic solutions that recently announced a strategic pivot from pharmaceutical development to begin focusing on the development and commercialization of direct-to-consumer skincare solutions. The Company is currently developing a first-of-its-kind skin renewal and OTC acne treatment that incorporates our Bioneedle. We plan to launch our first cosmetic product, called the Foundational Treatment, for a once weekly skin renewal under our Tome skincare brand in the middle of 2026 with the launch of our OTC acne Clearing Treatment to follow shortly thereafter. Visit tomeskincare.com to find more information on our Tome skincare products.

Investor Relations Contacts

Company

Dermata Therapeutics, Inc.
3525 Del Mar Heights Rd.
#322
San Diego, CA 92130

Investor Relations

Cliff Mastricola
T: 858-456-7300
cmastricola@dermatarx.com

Market Data copyright © 2026 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.